X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment

MT Newswires Live06-27

X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropenia yielded "positive interim clinical data".

Interim analysis of the ongoing six-month study indicated once-daily oral mavorixafor was well tolerated and consistently raised participants' absolute neutrophil counts, both alone and in combination with stable doses of injectable granulocyte colony-stimulating factor, X4 Pharmaceuticals said Thursday.

The company is screening patients for its global phase 3 trial, evaluating oral mavorixafor's efficacy in treating severe chronic neutropenia.

Intraday trading volume topped 5.8 million shares versus the daily average of 2.7 million.

Price: 0.70, Change: -0.30, Percent Change: -30.40

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446594195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-27 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446594195","market":"fut","top_or_hot":-1,"title":"X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropenia yielded \"positive interim clinical data\".</p><p>Interim analysis of the ongoing six-month study indicated once-daily oral mavorixafor was well tolerated and consistently raised participants' absolute neutrophil counts, both alone and in combination with stable doses of injectable granulocyte colony-stimulating factor, X4 Pharmaceuticals said Thursday.</p><p>The company is screening patients for its global phase 3 trial, evaluating oral mavorixafor's efficacy in treating severe chronic neutropenia.</p><p>Intraday trading volume topped 5.8 million shares versus the daily average of 2.7 million.</p><p>Price: 0.70, Change: -0.30, Percent Change: -30.40</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>X4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nX4 Pharmaceuticals Shares Fall After Trail Data Announced on Chronic Blood Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XFOR","symbol_name":"X4制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446594195","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446594195","pubTimestamp":1719499457,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XFOR":"X4制药","BK4139":"生物科技"},"translate_title":"慢性血液病治疗试验数据公布后，X4 Pharmaceuticals股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"X4 Pharmaceuticals (XFOR) shares fell 30% in recent Thursday trading even after the company said its phase 2 trial assessing the safety and efficacy of mavorixafor as a treatment for chronic neutropenia yielded \"positive interim clinical data\".Interim analysis of the ongoing six-month study indicated once-daily oral mavorixafor was well tolerated and consistently raised participants' absolute neutrophil counts, both alone and in combination with stable doses of injectable granulocyte colony-stimulating factor, X4 Pharmaceuticals said Thursday.The company is screening patients for its global phase 3 trial, evaluating oral mavorixafor's efficacy in treating severe chronic neutropenia.Intraday trading volume topped 5.8 million shares versus the daily average of 2.7 million.Price: 0.70, Change: -0.30, Percent Change: -30.40","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446594195"}